This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
ASCO 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2020
ESMO 2020
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ESMO Virtual Congress 2020 Kidney Cancer
Viewing 1-20 of 30 articles
ESMO Virtual Congress 2020: Cabozantinib in Combination with Atezolizumab in Non-Clear Cell Renal Cell Carcinoma: Results from Cohort 10 of the COSMIC-021 Study
ESMO Virtual Congress 2020: COSMIC-021, Cabozantinib in Combination with Atezolizumab as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma
ESMO Virtual Congress 2020: Invited Discussant (702O) the COSMIC-021 Trial and (LBA25) the French BIONIKK Trial
ESMO Virtual Congress 2020: Results From the Phase 2 BIOmarker Driven Trial with Nivolumab and Ipilimumab or VEGFR TKI in Naïve Metastatic Kidney Cancer: the BIONIKK Trial
ESMO Virtual Congress 2020: Kidney Cancer First-Line Treatment Clinical Trials: Invited Discussant (702O) the COSMIC-021 Trial and (LBA25) the French BIONIKK Trial
ESMO Virtual Congress 2020: Invited Discussant: Predictive Biomarkers in Metastatic Renal Cell Carcinoma
ESMO Virtual Congress 2020: Clear Cell Renal Cell Carcinoma Immune Classification Enhances the Predictive Value of T Effector and Angiogenesis Signatures in Response to Nivolumab
ESMO Virtual Congress 2020: Assessment of Circulating Cell-Free Tumor DNA in 847 Patients with Metastatic Renal Cell Carcinoma and Concordance with Tissue-Based Testing
ESMO Virtual Congress 2020: Results from the Phase 2 Biomarker Driven Trial with Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor in Naïve Metastatic Kidney Cancer Patients: The BIONIKK Trial
ESMO Virtual Congress 2020: Cabozantinib in Combination with Atezolizumab as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma: Results from the COSMIC-021 Study
ESMO Virtual Congress 2020: Assessment of Circulating Cell-Free Tumor DNA in 847 Patients with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing
ESMO Virtual Congress 2020: Predictive Biomarkers in Renal Cell Carcinoma
ESMO Virtual Congress 2020: Kidney ccRCC Immune Classification Enhances the Predictive Value of T Effector and Angiogenesis Signatures in Response to Nivolumab
ESMO Virtual Congress 2020: First Results From the Randomized Phase 3 CheckMate 9ER Trial: Nivolumab + Cabozantinib vs Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma
ESMO Virtual Congress 2020: Comparison of Long-Term Survival and Cost-Effectiveness of First-Line Treatment Options in Advanced Renal Cell Carcinoma with Intermediate or Poor Prognostic Risk
ESMO Virtual Congress 2020: A Phase II Study of Patients with Advanced or Metastatic Renal Cell Carcinoma (mRCC) Receiving Pazopanib After Previous Checkpoint Inhibitor Treatment
ESMO Virtual Congress 2020: Phase 2 Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lind Disease–Associated Clear Cell Renal Cell Carcinoma
ESMO Virtual Congress 2020: Phase 2 Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lind Disease–Associated Clear Cell Renal Cell Carcinoma: Update on RCC and Non-RCC Disease
ESMO Virtual Congress 2020: Invited Discussant: First Results From the Randomized Phase 3 CheckMate 9ER Trial
ESMO Virtual Congress 2020: Nivolumab + Cabozantinib vs Sunitinib in First-line Treatment for Advanced Renal Cell Carcinoma: First Results From The Randomized Phase 3 CheckMate 9ER Trial
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free